APA (7th ed.) Citation

Chaigneau, L., Lapp, E., Jai, T., Dobi, E., Martin, B., Curtit, E., & Nerich, V. (2025). Real-World Evidence of Long-Term Disease Control in HER2-Positive Metastatic Breast Cancer Patients Treated with a First-Line Combination of Trastuzumab and/or Pertuzumab Plus Chemotherapy. Cancers, 17(21), 3532. https://doi.org/10.3390/cancers17213532

Chicago Style (17th ed.) Citation

Chaigneau, Loïc, Eva Lapp, Taha Jai, Erion Dobi, Berenger Martin, Elsa Curtit, and Virginie Nerich. "Real-World Evidence of Long-Term Disease Control in HER2-Positive Metastatic Breast Cancer Patients Treated with a First-Line Combination of Trastuzumab And/or Pertuzumab Plus Chemotherapy." Cancers 17, no. 21 (2025): 3532. https://doi.org/10.3390/cancers17213532.

MLA (9th ed.) Citation

Chaigneau, Loïc, et al. "Real-World Evidence of Long-Term Disease Control in HER2-Positive Metastatic Breast Cancer Patients Treated with a First-Line Combination of Trastuzumab And/or Pertuzumab Plus Chemotherapy." Cancers, vol. 17, no. 21, 2025, p. 3532, https://doi.org/10.3390/cancers17213532.